Skip to Main Content

Advertisement intended for health care professionals

Umbrella Alt Text
Cart
header search
Search
Skip Nav Destination

Issue Archive

Volume 4, Issue 9
May 12 2020
Issue Cover

Table of Contents

CLINICAL GUIDELINES

A user guide to the American Society of Hematology clinical practice guidelines
Ariel Izcovich,Adam Cuker,Robert Kunkle,Ignacio Neumann,Julie Panepinto,Menaka Pai,Matthew Seftel,Matthew C. Cheung,Richard Lottenberg,Michael Byrne,Robert Plovnick,Deirdra Terrell,Jennifer L. Holter-Chakrabarty,Benjamin Djulbegovic,Lisa K. Hicks,Wojtek Wiercioch,Robby Nieuwlaat,Holger J. Schünemann
View Articletitled, A user guide to the American Society of Hematology clinical practice guidelines

TESTING ADVANCES

Laboratory monitoring of hemophilia A treatments: new challenges
Clinical Trials & Observations
Peter J. Lenting
View Articletitled, Laboratory monitoring of hemophilia A treatments: new challenges

STIMULUS REPORTS

Mutational dynamics and immune evasion in diffuse large B-cell lymphoma explored in a relapse-enriched patient series
Jillian F. Wise,Sigve Nakken,Chloé B. Steen,Daniel Vodák,Gunhild Trøen,Bjarne Johannessen,Ole Christian Lingjærde,Vera Hilden,Yngvild Nuvin Blaker,Baoyan Bai,Lars Birger Aasheim,Annika Pasanen,Susanne Lorenz,Anita Sveen,Ragnhild A. Lothe,Ola Myklebost,Sirpa Leppä,Leonardo A. Meza-Zepeda,Klaus Beiske,Michael S. Lawrence,Eivind Hovig,June Helen Myklebust,Erlend B. Smeland,Harald Holte
View Articletitled, Mutational dynamics and immune evasion in diffuse large B-cell lymphoma explored in a relapse-enriched patient series
Supplemental data
Maternal microchimerism protects hemophilia A patients from inhibitor development
Yeling Lu,Zhenping Chen,Jing Dai,Xi Wu,Hao Gu,Zekun Li,Jian Li,Qiulan Ding,Wenman Wu,Runhui Wu,Xuefeng Wang
View Articletitled, Maternal microchimerism protects hemophilia A patients from inhibitor development
Myelodysplastic syndrome unrelated to lentiviral vector in a patient treated with gene therapy for sickle cell disease
Clinical Trials & Observations
Matthew M. Hsieh,Melissa Bonner,Francis John Pierciey, Jr,Naoya Uchida,James Rottman,Laura Demopoulos,Manfred Schmidt,Julie Kanter,Mark C. Walters,Alexis A. Thompson,Mohammed Asmal,John F. Tisdale
View Articletitled, Myelodysplastic syndrome unrelated to lentiviral vector in a patient treated with gene therapy for sickle cell disease

CLINICAL TRIALS AND OBSERVATIONS

Patients with high-risk DLBCL benefit from dose-dense immunochemotherapy combined with early systemic CNS prophylaxis
Clinical Trials & Observations
Sirpa Leppä,Judit Jørgensen,Anne Tierens,Leo Meriranta,Ingunn Østlie,Peter de Nully Brown,Unn-Merete Fagerli,Thomas Stauffer Larsen,Susanna Mannisto,Lars Munksgaard,Martin Maisenhölder,Kaija Vasala,Peter Meyer,Mats Jerkeman,Magnus Björkholm,Øystein Fluge,Sirkku Jyrkkiö,Knut Liestøl,Elisabeth Ralfkiaer,Signe Spetalen,Klaus Beiske,Marja-Liisa Karjalainen-Lindsberg,Harald Holte
View Articletitled, Patients with high-risk DLBCL benefit from dose-dense immunochemotherapy combined with early systemic CNS prophylaxis
Supplemental data
The conditional survival analysis of relapsed DLBCL after autologous transplant: a subgroup analysis of LY.12 and CORAL
Clinical Trials & Observations
Sarit Assouline,Shen Li,Christian Gisselbrecht,Patrick Fogarty,Annette Hay,Eric van den Neste,Lois E. Shepherd,Norbert Schmitz,Tara Baetz,Armand Keating,Sue Robinson,Matthew Seftel,Caterina Stelitano,Marina S. Djurfeldt,Ralph Meyer,Bingshu E. Chen,Michael Crump
View Articletitled, The conditional survival analysis of relapsed DLBCL after autologous transplant: a subgroup analysis of LY.12 and CORAL
Supplemental data
Phase 1 study of CWP232291 in patients with relapsed or refractory acute myeloid leukemia and myelodysplastic syndrome
Clinical Trials & Observations
Je-Hwan Lee,Stefan Faderl,John M. Pagel,Chul Won Jung,Sung-Soo Yoon,Animesh D. Pardanani,Pamela S. Becker,Howard Lee,Jeongeun Choi,Kyoungjune Lee,Minkyoung Kim,Jorge E. Cortes
View Articletitled, Phase 1 study of CWP232291 in patients with relapsed or refractory acute myeloid leukemia and myelodysplastic syndrome
Supplemental data
Two distinct prognostic groups in advanced-stage Hodgkin lymphoma revealed by the presence and site of bulky disease
Clinical Trials & Observations
Shunan Qi,Sarah Milgrom,Bouthaina Dabaja,Richard Tsang,Mario Levis,Umberto Ricardi,Rebecca Lopez-Alonso,Eldad J. Dann,Andrea Ng,Joachim Yahalom
View Articletitled, Two distinct prognostic groups in advanced-stage Hodgkin lymphoma revealed by the presence and site of bulky disease
Supplemental data

HEMATOPOIESIS AND STEM CELLS

Induction of blood-circulating bile acids supports recovery from myelosuppressive chemotherapy
Clinical Trials & Observations
Valgardur Sigurdsson,Youichi Haga,Hajime Takei,Els Mansell,Chizuko Okamatsu-Haga,Mitsuyoshi Suzuki,Visnja Radulovic,Mark van der Garde,Shuhei Koide,Svetlana Soboleva,Mats Gåfvels,Hiroshi Nittono,Akira Ohara,Kenichi Miharada
View Articletitled, Induction of blood-circulating bile acids supports recovery from myelosuppressive chemotherapy
Supplemental data
The sialyltransferase ST3Gal-IV guides murine T-cell progenitors to the thymus
Selina Sitte,Daniela Doehler,Markus Sperandio,Jamey D. Marth,David Voehringer
View Articletitled, The sialyltransferase ST3Gal-IV guides murine T-cell progenitors to the thymus
Supplemental data

IMMUNOBIOLOGY AND IMMUNOTHERAPY

Safety and activity of varlilumab, a novel and first-in-class agonist anti-CD27 antibody, for hematologic malignancies
Stephen M. Ansell,Ian Flinn,Matthew H. Taylor,Branimir I. Sikic,Joshua Brody,John Nemunaitis,Andrew Feldman,Thomas R. Hawthorne,Tracey Rawls,Tibor Keler,Michael J. Yellin
View Articletitled, Safety and activity of varlilumab, a novel and first-in-class agonist anti-CD27 antibody, for hematologic malignancies
Supplemental data
Inducible MyD88/CD40 synergizes with IL-15 to enhance antitumor efficacy of CAR-NK cells
Xiaomei Wang,Daniel L. Jasinski,Jan L. Medina,David M. Spencer,Aaron E. Foster,J. Henri Bayle
View Articletitled, Inducible MyD88/CD40 synergizes with IL-15 to enhance antitumor efficacy of CAR-NK cells
Supplemental data

LYMPHOID NEOPLASIA

Activation of PERK-ATF4-CHOP pathway as a novel therapeutic approach for efficient elimination of HTLV-1–infected cells
Emi Ikebe,Sahoko Matsuoka,Kenta Tezuka,Madoka Kuramitsu,Kazu Okuma,Makoto Nakashima,Seiichiro Kobayashi,Junya Makiyama,Makoto Yamagishi,Seiichi Oyadomari,Kaoru Uchimaru,Isao Hamaguchi
View Articletitled, Activation of PERK-ATF4-CHOP pathway as a novel therapeutic approach for efficient elimination of HTLV-1–infected cells
Supplemental data
Adult T-cell leukemia/lymphoma incidence rate in French Guiana: a prospective cohort of women infected with HTLV-1
Clinical Trials & Observations Global Advances
Jill-Léa Ramassamy,Patricia Tortevoye,Balthazar Ntab,Béatrice Seve,Gabriel Carles,Dominique Gaquière,Yoann Madec,Arnaud Fontanet,Antoine Gessain
View Articletitled, Adult T-cell leukemia/lymphoma incidence rate in French Guiana: a prospective cohort of women infected with HTLV-1
Comparing transplant outcomes in ALL patients after haploidentical with PTCy or matched unrelated donor transplantation
Clinical Trials & Observations
Monzr M. Al Malki,Dongyun Yang,Myriam Labopin,Boris Afanasyev,Emanuele Angelucci,Asad Bashey,Gérard Socié,Amado Karduss-Urueta,Grzegorz Helbig,Martin Bornhauser,Riitta Niittyvuopio,Arnold Ganser,Fabio Ciceri,Arne Brecht,Yener Koc,Nelli Bejanyan,Francesca Ferraro,Partow Kebriaei,Sally Mokhtari,Armin Ghobadi,Ryotaro Nakamura,Stephen J. Forman,Richard Champlin,Mohamad Mohty,Stefan O. Ciurea,Arnon Nagler
View Articletitled, Comparing transplant outcomes in ALL patients after haploidentical with PTCy or matched unrelated donor transplantation
Supplemental data

MYELOID NEOPLASIA

Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AML
Clinical Trials & Observations
Sung Choe,Hongfang Wang,Courtney D. DiNardo,Eytan M. Stein,Stéphane de Botton,Gail J. Roboz,Jessica K. Altman,Alice S. Mims,Justin M. Watts,Daniel A. Pollyea,Amir T. Fathi,Martin S. Tallman,Hagop M. Kantarjian,Richard M. Stone,Lynn Quek,Zenon Konteatis,Lenny Dang,Brandon Nicolay,Parham Nejad,Guowen Liu,Vickie Zhang,Hua Liu,Meredith Goldwasser,Wei Liu,Kevin Marks,Chris Bowden,Scott A. Biller,Eyal C. Attar,Bin Wu
View Articletitled, Molecular mechanisms mediating relapse following ivosidenib monotherapy in <em>IDH1</em>-mutant relapsed or refractory AML
Supplemental data
Added prognostic value of secondary AML-like gene mutations in ELN intermediate-risk older AML: ALFA-1200 study results
Clinical Trials & Observations
Claude Gardin,Cécile Pautas,Elise Fournier,Raphaël Itzykson,Emilie Lemasle,Jean-Henri Bourhis,Lionel Adès,Jean-Pierre Marolleau,Jean-Valère Malfuson,Lauris Gastaud,Emmanuel Raffoux,Juliette Lambert,Thorsten Braun,Xavier Thomas,Sylvain Chantepie,Thomas Cluzeau,Stéphane de Botton,Céline Berthon,Nicolas Boissel,Nicolas Duployez,Christine Terré,Régis Peffault de Latour,Mauricette Michallet,Karine Celli-Lebras,Claude Preudhomme,Hervé Dombret
View Articletitled, Added prognostic value of secondary AML-like gene mutations in ELN intermediate-risk older AML: ALFA-1200 study results
Supplemental data

PLATELETS AND THROMBOPOIESIS

Inflammatory signaling in dengue-infected platelets requires translation and secretion of nonstructural protein 1
Anna Cecíllia Quirino-Teixeira,Stephane Vicente Rozini,Giselle Barbosa-Lima,Diego Rodrigues Coelho,Pedro Henrique Carneiro,Ronaldo Mohana-Borges,Patrícia T. Bozza,Eugenio D. Hottz
View Articletitled, Inflammatory signaling in dengue-infected platelets requires translation and secretion of nonstructural protein 1
Supplemental data

RED CELLS, IRON, AND ERYTHROPOIESIS

Clinical, laboratory, and genetic risk factors for thrombosis in sickle cell disease
Andrew Srisuwananukorn,Rasha Raslan,Xu Zhang,Binal N. Shah,Jin Han,Michel Gowhari,Robert E. Molokie,Victor R. Gordeuk,Santosh L. Saraf
View Articletitled, Clinical, laboratory, and genetic risk factors for thrombosis in sickle cell disease
Supplemental data
Development of an anti-human complement C6 monoclonal antibody that inhibits the assembly of membrane attack complexes
Kimberly Lin,Lingjun Zhang,Michael Kong,Maojing Yang,Yinghua Chen,Earl Poptic,Melanie Hoffner,Jijun Xu,Connie Tam,Feng Lin
View Articletitled, Development of an anti-human complement C6 monoclonal antibody that inhibits the assembly of membrane attack complexes
Supplemental data

THROMBOSIS AND HEMOSTASIS

FVIII half-life extension by coadministration of a D′D3 albumin fusion protein in mice, rabbits, rats, and monkeys
Sabine Pestel,Hans-Wilhelm Beltz,Philipp Claar,Holger Lind,Marcel Mischnik,Elmar Raquet,Arna Andrews,Jason Simmonds,Vesna Tomasetig,Steven K. Dower,Anna Tjärnlund-Wolf,Stefan Schulte,Peter M. Schmidt,Thomas Weimer
View Articletitled, FVIII half-life extension by coadministration of a D′D3 albumin fusion protein in mice, rabbits, rats, and monkeys
Supplemental data

TRANSFUSION MEDICINE

Mesenchymal stromal cell therapeutic potency is dependent upon viability, route of delivery, and immune match
Jayeeta Giri,Jacques Galipeau
View Articletitled, Mesenchymal stromal cell therapeutic potency is dependent upon viability, route of delivery, and immune match
Supplemental data

TRANSPLANTATION

Functional and phylogenetic alterations in gut microbiome are linked to graft-versus-host disease severity
Mathilde Payen,Ioannis Nicolis,Marie Robin,David Michonneau,Johanne Delannoye,Camille Mayeur,Nathalie Kapel,Béatrice Berçot,Marie-José Butel,Jérôme Le Goff,Gérard Socié,Clotilde Rousseau
View Articletitled, Functional and phylogenetic alterations in gut microbiome are linked to graft-versus-host disease severity
Supplemental data
BK virus–specific T-cell immune reconstitution after allogeneic hematopoietic cell transplantation
Eduardo Espada,Matthew P. Cheng,Haesook T. Kim,Ann E. Woolley,Jason I. Avigan,Edouard Forcade,Maria V. D. Soares,João F. Lacerda,Sarah Nikiforow,Mahasweta Gooptu,Rizwan Romee,Edwin P. Alyea,Philippe Armand,Corey S. Cutler,Vincent T. Ho,John Koreth,Joseph H. Antin,Robert J. Soiffer,Francisco M. Marty,Jerome Ritz
View Articletitled, BK virus–specific T-cell immune reconstitution after allogeneic hematopoietic cell transplantation
Supplemental data
Survival following allogeneic transplant in patients with myelofibrosis
Clinical Trials & Observations
Krisstina Gowin,Karen Ballen,Kwang Woo Ahn,Zhen-Huan Hu,Haris Ali,Murat O. Arcasoy,Rebecca Devlin,Maria Coakley,Aaron T. Gerds,Michael Green,Vikas Gupta,Gabriela Hobbs,Tania Jain,Malathi Kandarpa,Rami Komrokji,Andrew T. Kuykendall,Kierstin Luber,Lucia Masarova,Laura C. Michaelis,Sarah Patches,Ashley C. Pariser,Raajit Rampal,Brady Stein,Moshe Talpaz,Srdan Verstovsek,Martha Wadleigh,Vaibhav Agrawal,Mahmoud Aljurf,Miguel Angel Diaz,Belinda R. Avalos,Ulrike Bacher,Asad Bashey,Amer M. Beitinjaneh,Jan Cerny,Saurabh Chhabra,Edward Copelan,Corey S. Cutler,Zachariah DeFilipp,Shahinaz M. Gadalla,Siddhartha Ganguly,Michael R. Grunwald,Shahrukh K. Hashmi,Mohamed A. Kharfan-Dabaja,Tamila Kindwall-Keller,Nicolaus Kröger,Hillard M. Lazarus,Jane L. Liesveld,Mark R. Litzow,David I. Marks,Sunita Nathan,Taiga Nishihori,Richard F. Olsson,Attaphol Pawarode,Jacob M. Rowe,Bipin N. Savani,Mary Lynn Savoie,Sachiko Seo,Melhem Solh,Roni Tamari,Leo F. Verdonck,Jean A. Yared,Edwin Alyea,Uday Popat,Ronald Sobecks,Bart L. Scott,Ryotaro Nakamura,Ruben Mesa,Wael Saber
View Articletitled, Survival following allogeneic transplant in patients with myelofibrosis
Supplemental data
Targeted busulfan-based reduced-intensity conditioning and HLA-matched HSCT cure hemophagocytic lymphohistiocytosis
Clinical Trials & Observations
Matthias Felber,Colin G. Steward,Karim Kentouche,Anders Fasth,Robert F. Wynn,Ulrike Zeilhofer,Veronika Haunerdinger,Benjamin Volkmer,Seraina Prader,Bernd Gruhn,Stephan Ehl,Kai Lehmberg,Daniel Müller,Andrew R. Gennery,Michael H. Albert,Fabian Hauck,Kanchan Rao,Paul Veys,Moustapha Hassan,Arjan C. Lankester,Jana Pachlopnik Schmid,Mathias M. Hauri-Hohl,Tayfun Güngör,on behalf of the Inborn Errors Working Party (IEWP) of the European Society for Blood and Marrow Transplantation (EBMT) and the European Society of Immunodeficiencies (ESID),on behalf of the Inborn Errors Working Party (IEWP) of the European Society for Blood and Marrow Transplantation (EBMT) and the European Society of Immunodeficiencies (ESID),on behalf of the Inborn Errors Working Party (IEWP) of the European Society for Blood and Marrow Transplantation (EBMT) and the European Society of Immunodeficiencies (ESID),on behalf of the Inborn Errors Working Party (IEWP) of the European Society for Blood and Marrow Transplantation (EBMT) and the European Society of Immunodeficiencies (ESID),on behalf of the Inborn Errors Working Party (IEWP) of the European Society for Blood and Marrow Transplantation (EBMT) and the European Society of Immunodeficiencies (ESID),on behalf of the Inborn Errors Working Party (IEWP) of the European Society for Blood and Marrow Transplantation (EBMT) and the European Society of Immunodeficiencies (ESID),on behalf of the Inborn Errors Working Party (IEWP) of the European Society for Blood and Marrow Transplantation (EBMT) and the European Society of Immunodeficiencies (ESID),on behalf of the Inborn Errors Working Party (IEWP) of the European Society for Blood and Marrow Transplantation (EBMT) and the European Society of Immunodeficiencies (ESID),on behalf of the Inborn Errors Working Party (IEWP) of the European Society for Blood and Marrow Transplantation (EBMT) and the European Society of Immunodeficiencies (ESID),on behalf of the Inborn Errors Working Party (IEWP) of the European Society for Blood and Marrow Transplantation (EBMT) and the European Society of Immunodeficiencies (ESID),on behalf of the Inborn Errors Working Party (IEWP) of the European Society for Blood and Marrow Transplantation (EBMT) and the European Society of Immunodeficiencies (ESID),on behalf of the Inborn Errors Working Party (IEWP) of the European Society for Blood and Marrow Transplantation (EBMT) and the European Society of Immunodeficiencies (ESID),on behalf of the Inborn Errors Working Party (IEWP) of the European Society for Blood and Marrow Transplantation (EBMT) and the European Society of Immunodeficiencies (ESID),on behalf of the Inborn Errors Working Party (IEWP) of the European Society for Blood and Marrow Transplantation (EBMT) and the European Society of Immunodeficiencies (ESID),on behalf of the Inborn Errors Working Party (IEWP) of the European Society for Blood and Marrow Transplantation (EBMT) and the European Society of Immunodeficiencies (ESID),on behalf of the Inborn Errors Working Party (IEWP) of the European Society for Blood and Marrow Transplantation (EBMT) and the European Society of Immunodeficiencies (ESID),on behalf of the Inborn Errors Working Party (IEWP) of the European Society for Blood and Marrow Transplantation (EBMT) and the European Society of Immunodeficiencies (ESID),on behalf of the Inborn Errors Working Party (IEWP) of the European Society for Blood and Marrow Transplantation (EBMT) and the European Society of Immunodeficiencies (ESID),on behalf of the Inborn Errors Working Party (IEWP) of the European Society for Blood and Marrow Transplantation (EBMT) and the European Society of Immunodeficiencies (ESID),on behalf of the Inborn Errors Working Party (IEWP) of the European Society for Blood and Marrow Transplantation (EBMT) and the European Society of Immunodeficiencies (ESID),on behalf of the Inborn Errors Working Party (IEWP) of the European Society for Blood and Marrow Transplantation (EBMT) and the European Society of Immunodeficiencies (ESID),on behalf of the Inborn Errors Working Party (IEWP) of the European Society for Blood and Marrow Transplantation (EBMT) and the European Society of Immunodeficiencies (ESID),on behalf of the Inborn Errors Working Party (IEWP) of the European Society for Blood and Marrow Transplantation (EBMT) and the European Society of Immunodeficiencies (ESID)
View Articletitled, Targeted busulfan-based reduced-intensity conditioning and HLA-matched HSCT cure hemophagocytic lymphohistiocytosis
Supplemental data
Subsequent neoplasms and late mortality in children undergoing allogeneic transplantation for nonmalignant diseases
Clinical Trials & Observations
Justine M. Kahn,Ruta Brazauskas,Heather R. Tecca,Stephanie Bo-Subait,David Buchbinder,Minoo Battiwala,Mary E. D. Flowers,Bipin N. Savani,Rachel Phelan,Larisa Broglie,Allistair A. Abraham,Amy K. Keating,Andrew Daly,Baldeep Wirk,Biju George,Blanche P. Alter,Celalettin Ustun,Cesar O. Freytes,Amer M. Beitinjaneh,Christine Duncan,Edward Copelan,Gerhard C. Hildebrandt,Hemant S. Murthy,Hillard M. Lazarus,Jeffery J. Auletta,Kasiani C. Myers,Kirsten M. Williams,Kristin M. Page,Lynda M. Vrooman,Maxim Norkin,Michael Byrne,Miguel Angel Diaz,Naynesh Kamani,Neel S. Bhatt,Andrew Rezvani,Nosha Farhadfar,Parinda A. Mehta,Peiman Hematti,Peter J. Shaw,Rammurti T. Kamble,Raquel Schears,Richard F. Olsson,Robert J. Hayashi,Robert Peter Gale,Samantha J. Mayo,Saurabh Chhabra,Seth J. Rotz,Sherif M. Badawy,Siddhartha Ganguly,Steven Pavletic,Taiga Nishihori,Tim Prestidge,Vaibhav Agrawal,William J. Hogan,Yoshihiro Inamoto,Bronwen E. Shaw,Prakash Satwani
View Articletitled, Subsequent neoplasms and late mortality in children undergoing allogeneic transplantation for nonmalignant diseases
Supplemental data

COMMENTARIES

Poor tolerability to ponatinib in Indian CML patients
Clinical Trials & Observations
Charanpreet Singh,Arihant Jain,Deepesh Lad,Gaurav Prakash,Alka Khadwal,Dinesh Bhurani,Rayaz Ahmed,Narendra Agrawal,Jose Easow,Neelam Varma,Pankaj Malhotra
View Articletitled, Poor tolerability to ponatinib in Indian CML patients
Significance of antinuclear antibodies in primary immune thrombocytopenia: results of the CARMEN registry
Guillaume Moulis,Thibault Comont,Johanne Germain,Agnès Sommet,Maryse Lapeyre-Mestre,Odile Beyne-Rauzy,Daniel Adoue,and the CARMEN investigators group
View Articletitled, Significance of antinuclear antibodies in primary immune thrombocytopenia: results of the CARMEN registry
Supplemental data

ERRATA

Bai X, Huang L, Niu L, et al. Mst1 positively regulates B-cell receptor signaling via CD19 transcriptional levels. Blood Adv. 2016;1(3):219-230.
View Articletitled, Bai X, Huang L, Niu L, et al. Mst1 positively regulates B-cell receptor signaling via CD19 transcriptional levels. <em>Blood Adv.</em> 2016;1(3):219-230.
Huang L, Sun X, Yang D, et al. WASP and Mst1 coregulate B-cell development and B-cell receptor signaling. Blood Adv. 2020;4(3):573-585.
View Articletitled, Huang L, Sun X, Yang D, et al. WASP and Mst1 coregulate B-cell development and B-cell receptor signaling. <em>Blood Adv.</em> 2020;4(3):573-585.
  • Cover Image

    Cover Image

    issue cover

    COVER FIGURE
    Interactions between CD27, varlilumab, and the antigen-specific T-cell receptor (TCR) in the immune activation of effector T cells. APC, antigen-presenting cell; MHC, major histocompatibility complex. See the article by Ansell et al.

  • PDF Icon PDF LinkFront Matter
  • PDF Icon PDF LinkEditorial Board
All Issues

Advertisement intended for health care professionals

Where there is smoke, there is fire: afib in SCD
Deferiprone and idiosyncrasic neutropenia: light and shadow
Nording H, Baron L, Sauter M, et al. Platelets regulate ischemia-induced revascularization and angiogenesis by secretion of growth factor–modulating factors. Blood Adv. 2023;7(21):6411-6427.
Sewastianik T, Guerrera ML, Adler K, et al. Human MYD88L265P is insufficient by itself to drive neoplastic transformation in mature mouse B cells. Blood Adv. 2019;3(21):3360-3374.
Medicaid Coverage Continuity is Associated with Lymphoma Stage among Children and Adolescents/Young Adults

Advertisement intended for health care professionals

Advertisement intended for health care professionals

  • American Society of Hematology
  • 2021 L Street NW, Suite 900
  • Washington, DC 20036
  • TEL +1 202-776-0544
  • FAX +1 202-776-0545

ASH Publications

American Society of Hematology

Copyright 2024 by American Society of Hematology
 
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal

Advertisement intended for health care professionals